Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom

Constellation Brands (STZ) shares recently rebounded 8% to $143 after hitting multi-year lows, driven by a Q2 2026 earnings report that, despite a revenue miss at $2.48 billion, significantly beat adjusted EPS forecasts at $3.63 and showed gross margin expansion to 52.8%, with full-year guidance maintained. While the consensus price target suggests a 31% rally, updated analyst forecasts post-earnings are more conservative at an average of $163, indicating a slower recovery. The company benefits from demographic tailwinds, particularly the growing Hispanic American population, and recent scientific reviews largely debunk concerns about GLP-1 drugs impacting alcohol consumption, supporting a strong long-term potential and favorable risk-reward profile.

Analysis

Constellation Brands (STZ) recently rebounded 8% to $143 after hitting multi-year lows, following its Q2 2026 earnings report. Despite a 15% revenue decline to $2.48 billion, the company significantly beat adjusted EPS forecasts at $3.63, supported by a 100 basis point increase in gross margin to 52.8%. Shares gained 3% post-report.

The firm maintained its full-year guidance, signaling a stable outlook. However, updated Wall Street analyst price targets average $163, a more conservative 14% upside versus the prior $189 consensus, suggesting a longer recovery trajectory.

A significant tailwind is the growing Hispanic American population in the U.S., accounting for 50% of its beer sales. Concerns regarding GLP-1 drugs impacting alcohol consumption appear largely unfounded, with recent reviews finding little evidence of a link.

Trading barely above its five-year low, downside potential seems limited, while substantial upside exists given robust brands and favorable demographic trends. This presents a compelling long-term risk-reward profile, with shares 85% below their all-time high.

Key Decisions for Investors

• Long-term investors may consider current valuation levels, given the favorable risk-reward profile and significant upside potential from its all-time high.
• Monitor future analyst revisions and company guidance closely, as updated price targets suggest a more protracted recovery despite recent earnings beats.
• Assess the ongoing scientific research regarding GLP-1 drug impacts on consumer behavior, although current evidence largely debunks this as a material headwind for alcohol consumption.